Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

U.S. FDA Approves PREVNAR 20®, Pfizer's 20-valent Pneumococcal Conjugate Vaccine for Infants and Children

Business Wire April 27, 2023

Pfizer Declares Second-Quarter 2023 Dividend

Business Wire April 26, 2023

AM Best Affirms Credit Ratings of Blue Whale Re Ltd.

Business Wire April 21, 2023

Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27

Business Wire April 13, 2023

Pfizer (NYSE:PFE), others blast Texas abortion pill ruling

Simon Druker  April 10, 2023

Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech

GlobeNewswire April 4, 2023

FDA Accepts Pfizer's Supplemental New Drug Applications for BRAFTOVI + MEKTOVI

Business Wire April 4, 2023

Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts

Business Wire March 21, 2023

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

PR Newswire March 16, 2023

FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer's PAXLOVID(TM)

Business Wire March 16, 2023

SHAREHOLDER ALERT: Weiss Law Investigates Seagen Inc.

PR Newswire March 14, 2023

Astellas Announces Phase 3 China ARCHES Study of XTANDI® Meets Primary Endpoint

PR Newswire March 13, 2023

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Seagen Inc.

PR Newswire March 13, 2023

Pfizer (NYSE:PFE) acquiring cancer-focused biotech

Simon Druker  March 13, 2023

Pfizer Invests $43 Billion to Battle Cancer

Business Wire March 13, 2023

Pfizer's ZAVZPRET(TM) (zavegepant) Migraine Nasal Spray Receives FDA Approval

Business Wire March 10, 2023

Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults

Business Wire February 28, 2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire February 27, 2023

Pfizer's Elranatamab Receives FDA and EMA Filing Acceptance

Business Wire February 22, 2023

U.S. FDA Accepts Biologics License Application for Pfizer's Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review

Business Wire February 21, 2023